Immutep (NASDAQ:IMMP) Shares Cross Below 50 Day Moving Average – Here’s Why

Immutep Limited (NASDAQ:IMMP) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $1.90 and traded as low as $1.76. Immutep shares last traded at $1.76, with a volume of 110,154 shares.

Immutep Stock Performance

The firm’s fifty day moving average is $1.90 and its two-hundred day moving average is $1.99. The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Immutep

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMMP. Fortitude Advisory Group L.L.C. bought a new position in Immutep in the 4th quarter valued at $28,000. XY Capital Ltd lifted its stake in shares of Immutep by 52.0% in the 4th quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company’s stock valued at $357,000 after acquiring an additional 56,306 shares during the last quarter. ABC Arbitrage SA purchased a new stake in shares of Immutep during the fourth quarter valued at approximately $152,000. OLD Mission Capital LLC bought a new stake in Immutep in the 4th quarter worth $36,000. Finally, Two Sigma Securities LLC purchased a new stake in Immutep in the 4th quarter worth approximately $74,000. 2.32% of the stock is currently owned by institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.